Ironwood pharmaceuticals, inc. (IRWD)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net Income (Loss)

21,505

-282,368

-116,937

-81,708

-142,669

-189,618

-272,812

-72,624

-64,852

-51,860

-73,312

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization

5,580

3,859

6,442

10,300

11,630

12,331

11,729

11,325

9,999

6,161

4,763

Income from discontinued operations

-

-

-

-

-

-

-

-

-

4,551

-13,314

Net loss from continuing operations

-

-

-

-

-

-

-

-

-

-56,411

-59,998

Amortization of acquired intangible assets

-

8,111

6,214

981

-

-

-

-

-

-

-

Impairment of intangible assets

-

151,800

-

-

-

-

-

-

-

-

-

Loss on disposal of property and equipment

-146

1,867

-694

204

196

-119

-610

-20

-7

-474

-80

Remeasurement of forward purchase contracts

-

-

-

-

-

-

-

-

-

-

600

Share-based compensation expense

31,278

40,526

30,905

29,219

25,469

26,184

19,829

17,573

11,732

7,496

5,095

Gain on lease modification

3,169

-

-

-

-

-

-

-

-

-

-

Change in fair value of note hedge warrants

16,232

-58,425

-21,049

37,909

4,479

-

-

-

-

-

-

Change in fair value of convertible note hedges

-19,255

67,168

24,333

-46,055

5,449

-

-

-

-

-

-

Write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments

-3,530

219

1,313

374

17,638

20,292

-

-

-

-

-

Write-down of excess non-cancellable ZURAMPIC and DUZALLO sample purchase commitments

-

390

309

-

-

-

-

-

-

-

-

Gain on facility subleases

-

-

1,579

-3,480

-296

-2,573

-

-

-

-

-

Accretion of discount/premium on investment securities

-

165

75

-667

-1,114

-1,085

-1,254

-1,157

-2,234

-1,619

-239

Non-cash interest expense

19,590

17,601

16,080

14,812

8,102

1,566

1,719

-

-

-

-

Non-cash change in fair value of contingent consideration

-

-31,045

-31,310

9,831

-

-

-

-

-

-

-

Loss on extinguishment of debt

-31,000

-

-2,009

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable and related party accounts receivable, net

68,893

-1,207

17,303

10,336

28,679

23,680

1,726

835

-2,243

-2,324

648

Restricted cash

-

-

-

-

600

-

500

-

-2,833

2,348

446

Prepaid expenses and other current assets

1,046

3,727

-2,271

3,069

-2,568

3,947

52

5,127

-2,421

2,647

464

Inventory, net

-

806

-346

-

-

3,078

11,915

6,699

-

-

-

Other assets

-159

-702

-195

-1,643

-414

2,876

-116

145

-136

253

-50

Accounts payable, related party accounts payable and accrued expenses

-32,700

2,678

-7,725

19,683

-1,551

1,425

-11,724

24,241

5,086

2,740

1,732

Accrued research and development costs

-483

542

-2,120

2,692

671

162

-2,252

-1,346

-1,130

-4,261

2,990

Deferred revenue

875

-

-

-8,989

-7,191

744

-4,915

-36,016

-45,012

-23,569

53,993

Operating lease right-of-use assets

-14,141

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-12,046

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

916

-1,053

-7,143

-3,871

1,811

-2,716

-2,149

-934

6,745

1,279

Other liabilities

-

-

-

-

-

-661

-

992

-

-

-

Net cash provided by (used in) continuing operating activities

-639

-82,690

-108,040

-

-

-

-273,355

-

-

-61,930

8,065

Net cash provided by discontinued operating activities

11,364

11,808

7,287

-

-

-

-

-

-

-5,969

-11,510

Net cash provided by (used in) operating activities

10,725

-70,882

-100,753

-25,934

-106,927

-155,568

-

-69,633

-75,237

-67,899

-3,445

Cash flows from investing activities:
Purchases of available-for-sale securities

-

3,241

191,354

311,116

281,958

253,995

287,943

96,709

97,511

441,799

26,673

Sales and maturities of available-for-sale securities

-

99,165

346,890

237,423

276,707

200,964

196,102

140,757

222,254

236,475

48,455

Purchases of property and equipment

7,189

351

2,803

4,206

4,049

3,538

9,592

13,979

9,682

17,220

3,524

Payment for acquisition of lesinurad license

-

-

-

100,000

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

268

1,563

135

225

147

-

-

9

4

1

21

Proceeds from sale of subsidiary

-

-

-

-

-

-

-

-

-

9,500

-

Net cash (used in) provided by continuing investing activities

-6,921

97,136

152,868

-

-

-

-101,433

-

-

-213,043

18,279

Net cash used in discontinued investing activities

-4,223

-8,270

-1,408

-

-

-

-

-

-

1

-521

Net cash used in investing activities

-11,144

88,866

151,460

-177,674

-9,153

-56,569

-

30,078

115,065

-213,042

17,758

Cash flows from financing activities:
Proceeds from issuance of convertible senior notes

400,000

-

-

-

335,699

-

-

-

-

-

-

Purchase of capped calls

25,159

-

-

-

-

-

-

-

-

-

-

Proceeds from partial termination of convertible note hedges and note hedge warrants

3,174

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of note hedge warrants

-

-

-

-

70,849

-

-

-

-

-

-

Purchase of convertible note hedges

-

-

-

-

-91,915

-

-

-

-

-

-

Costs associated with issuance of convertible senior notes

9,048

-

-

-

11,730

-

-

-

-

-

-

Proceeds from exercise of stock options and employee stock purchase plan

13,595

32,061

26,370

24,841

14,196

22,741

-

-

-

-

-

Payments on capital lease obligations

-

1,824

3,234

1,903

1,317

1,062

768

275

260

-

-

Payments for partial repurchase of 2022 Convertible Notes

227,338

-

-

-

-

-

-

-

-

-

-

Payments on 2026 Notes

156,409

-

-

-

-

-

-

-

-

-

-

Principal payments on PhaRMA notes

-

-

134,258

26,868

12,712

1,163

-

-

-

1,957

1,250

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

40,250

Proceeds from initial public offering

-

-

-

-

-

-

-

-

-

203,167

-

Proceeds from issuance of common stock

-

-

-

-

-

190,428

137,766

85,228

-

-

-

Proceeds from issuance of PhaRMA notes payable

-

-

-

-

-

-

175,000

-

-

-

-

Costs associated with issuance of 2026 Notes

-

-

235

246

-

-

7,717

-

-

-

-

Proceeds from issuance of 2026 Notes, net of discount to lender

-

-

146,250

-

-

-

-

-

-

-

-

Payments on contingent purchase price consideration

-

165

15,058

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options, and shares issued under employee stock purchase plan

-

-

-

-

-

-

9,297

4,020

3,393

2,023

272

Proceeds from borrowings

-

-

-

-

-

-

-

-

-

-

1,079

Net cash provided by (used in) continuing financing activities

-1,185

30,072

19,835

-

-

-

313,578

-

-

203,233

40,351

Net cash used in financing activities from discontinued operations

-

-

-

-

-

-

-

-

-

-277

1,312

Net cash provided by (used in) financing activities

-1,185

30,072

19,835

-4,176

303,070

210,944

-

88,973

3,133

202,956

41,663

Net increase (decrease) in cash, cash equivalents and restricted cash

-1,604

48,056

70,542

-207,784

186,990

-1,193

-61,210

49,418

42,961

-77,985

55,976

Supplemental cash flow disclosure:
Cash paid for interest

17,584

18,235

20,388

24,473

22,742

19,606

18,428

55

64

325

412

Cash paid for income taxes

-

-

-

-

-

-

-

-

3

-

-153

Non-cash investing and financing activities
Contingent consideration

-

-

-

67,885

-

-

-

-

-

-

-

Settlement of forward purchase contracts

-

-

-

-

-

-

-

-

-

-

-15,300

Purchases under capital leases

-

664

1,151

6,277

2,957

766

4,472

247

325

529

67

Extinguishment of capital leases

-

2,687

149

-1,001

2,529

-

-

-

-

-

-

Fixed asset purchases in accounts payable and accrued expenses

1,282

439

1,136

353

98

1,592

261

2,146

-

-

-

Debt and interest paid by purchaser of subsidiary

-

-

-

-

-

-

-

-

-

1,075

-